A double-blind, phase I clinical trial of Lomecel-B, an allogeneic bone marrow MSC preparation, reported improved cognitive outcomes and reductions in serum IL-6, alongside increased IL-4 and IL-10 in 25 patients with mild AD [40]. Here, IL6 is linked to Alzheimer disease.